The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca

Abstract

Results suggest that in a real-world setting tCSA is an effective treatment for patients suffering from KCS. Onset of relief may be more rapid than in previously published reports.

Efficacy and Safety of 0.05 % Cyclosporine Ophthalmic Microemulsion for the treatment of Moderate to Severe Dry Eye Disease – an Indian Experience

“…15 Reduction in use of artifi cial tear after 4 week treatment reported by 79.41% patients in our study is higher than, >60% patients reporting for reduction in use of artifi cial tear at 30 days, in a previous study. 23 The most important safety fi ndings of study were few adverse events (all non-serious) and no ocular infection; indicating that the treatment with cyclosporine 0.05% ophthalmic microemulsion in our study was well tolerated. Redness and heaviness, burning sensation and eye irritation are known adverse reactions to cyclosporine 0.05%.…”

Tissue‐engineered tear secretory system: Functional lacrimal gland acinar cells cultured on matrix protein‐coated substrata

“…Drugs like topical cyclosporine (Restasis ® ) have also been used for the treatment of dry eyes, but these drugs only target the inflammatory processes occurring in certain forms of the disease. 9 Patients with nonfunctioning lacrimal glands or blocked ducts (such as those with Stevens-Johnson syndrome), chemical or thermal injuries, or ocular cicatricial pemphigoid (an inflammatory syndrome involving the ocular mucous membranes) have very limited options because of the short duration and action of lubricating agents. A possible solution in providing long-term treatment for this diverse group of patients may lie in harnessing the principles of tissue-engineering to fabricate medical devices that provide tears to moisturize the ocular surface.…”

Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation

“…A Several studies 5,6 report that cyclosporine 0.05% significantly increases tear production and decreases the intensity of ocular staining and the severity of symptoms in patients with moderate to severe dry eye. Other studies 5,7 report that topical cyclosporine 0.05% therapy improved the quality of vision in patients with dry eye and decreased their dependency on artificial tears. Therefore, topical administration of cyclosporine 0.05% before and after cataract surgery may help prevent dry eye, improve ocular surface regularity, and increase visual quality.…”